National Research Registry for Blood Cancer Experiences

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The LLS National Research Registry collects real-world experiences and medical outcomes from individuals diagnosed with blood cancer, tracking their journey before, during, and after treatment. This observational registry gathers patient information and medical data over time to answer critical research questions related to blood cancers. Participants can choose to upload their medical records and provide consent for their data to be shared with research partners to advance treatment options.

Why it matters

Who can join: the full rules

Inclusion Criteria:

People with blood cancer, before, during, and after blood cancer treatments.

Exclusion Criteria:

People unable or unwilling to sign informed consent.

Where it's running

• Lymphoma and Leukemia Society
  Rye Brook, New York, United States Recruiting

Study contacts

• Study coordinator: Larry Saltzman, MD
• Email: larry.saltzman@lls.org
• Phone: 844-696-7228

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Genetics of Blood Cancers in the U.S. population

  This study tests how genetic factors relate to blood cancers by collecting saliva DNA and online health surveys from at least 10,000 U.S. adults.

  Recruiting Rutgers, The State University of New Jersey · Piscataway, New Jersey · NCT07714044

• Multi-biomarker panel to predict prognosis and treatment response in intestinal acute graft-versus-host disease

  This study will test whether a set of clinical and lab biomarkers can predict who will do well or poorly and who will respond to treatment for intestinal acute GvHD after an allogeneic stem cell transplant.

  Recruiting IRCCS Azienda Ospedaliero-Universitaria di Bologna · Bologna, Bologna · NCT07305090

• Targeting measurable residual AML with tagraxofusp plus azacitidine and venetoclax

  This trial tests whether adding tagraxofusp to azacitidine and venetoclax can safely help control measurable residual acute myeloid leukemia (AML) in adults who are in remission but still have detectable disease.

  Recruiting at 2 sites Phase 1/2 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT07148180

• Telehealth music therapy for cognitive difficulties in blood cancer survivors

  This program will test whether telehealth music therapy can help adults who survived leukemia, lymphoma, or myeloma and who are having trouble with memory, attention, or thinking.

  Recruiting at 7 sites Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07052916

• Personalized T cells engineered to target TP53 or RAS mutations in blood cancers

  This trial will try using a patient's own T cells, modified to recognize specific TP53 or RAS mutations, to treat adults with certain blood cancers.

  Recruiting Phase 1 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT06904066

• Pharmacogenomics to improve voriconazole dosing for fungal infections

  This trial will test whether using a patient's CYP2C19 genotype with Bayesian dosing software helps get voriconazole levels into the therapeutic range by Day 8 for people with fungal infections, including those with blood cancers.

  Recruiting at 7 sites Phase 2 The University of Queensland · Seattle, Washington and 6 other locations · NCT06510699

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.